OneSource Specialty Pharma Re-designates Dr. Claudio Albrecht as Non-Executive Director
Onesource Specialty Pharma Ltd 路 Change in Management 路 27 Oct 2026, 3:43 pm
OneSource Specialty Pharma Re-designates Dr. Claudio Albrecht as Non-Executive Director OneSource Specialty Pharma's Board approved the redesignation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, effective 27th Oct'26, subject to shareholder approval. Dr. Albrecht brings over three decades of global pharma experience, having previously served as CEO of Ratiopharm Group, Actavis Group, and STADA AG, as well as Co-Founder and Managing Partner of Albrecht, Prock & Partners AG. The position is liable to retirement by rotation in accordance with statutory provisions.
Original exchange filing (PDF)
More announcements from Onesource Specialty Pharma Ltd
- Intimation of resignation of Senior Management Personnel 路 17 Nov 2026
- Onesource Specialty Pharma Limited has informed the Exchange about the Participation in Jefferies Global Healthcare Conference to be held from November 16, 2026 to November 19, 2026 in London. 路 05 Nov 2026
- Intimation of Transcript of Earnings call dated October 27, 2026 路 03 Nov 2026
- OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru. 路 30 Oct 2026
- Intimation of the Audio recording of the earnings call pertaining to the unaudited financial results for the quarter and half year ended September 30, 2026 路 28 Oct 2026
- OneSource announces strong Q2FY27, results revenue up 37% YoY and EBITDA up 53% YoY 路 27 Oct 2026
- Intimation of allotment of 360 equity shares of Re.1/- each under ONESOURCE ESOP 2021 on October 27, 2026. 路 27 Oct 2026
- Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. 路 27 Oct 2026
